

# SINUVA Reimbursement Guide



## Coding and Billing

ICD-10-CM CODES	DESCRIPTOR
J33.0	Polyp of nasal cavity
J33.1	Polypoid sinus degeneration
J33.8	Other polyp of sinus
J33.9	Nasal polyp, unspecified

HCPCS	BILLING UNITS	DESCRIPTOR
J7401	1 unit for every 10 mcg = 135 billing units	Mometasone furoate sinus implant, 10 micrograms

  

NDC NUMBER	DESCRIPTOR
10599000301	SINUVA (mometasone furoate) 1350 mcg

Multiple procedure modifiers do not apply to HCPCS Codes.

## CPT® Codes

Providers should report the CPT code(s) which most accurately describe the services performed in association with placement of a drug-eluting sinus implant.

## Physician Office Billing

Example of CMS-1500 paper claim form submission.

The image shows a portion of a CMS-1500 claim form. Callout A points to the ICD-10-CM diagnosis code 'XXX.X' in Box 21. Callout B points to the NDC code 'N410599000301 UN2' in the shaded area of Box 24. Callout C points to the CPT code 'XXXXX' in Box 24. Callout D points to the HCPCS code 'J7401' in Box 24. Callout E points to the billing units 'XXX' in Box 24.

- A** ICD-10-CM Diagnosis Code.
- B** When entering supplemental information for the NDC, add the following in the shaded area of Box 24: N4 qualifier, 11 digit NDC code (insert one space) and UN followed by the quantity. UN1 is inserted for SINUVA unilateral procedures and UN2 is used for bilateral procedures.
- C** Report applicable CPT Procedure Code.
- D** Report HCPCS Code J7401 for SINUVA.
- E** If reporting unilateral/1 unit of SINUVA, input 135 units. If reporting bilateral/2 units of SINUVA, input 270 units.

The information above is provided for the benefit of Intersect ENT customers and offers general coverage, coding and payment information; it is not legal advice or instruction on how to code. CPT copyright 2019 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.

## DISCLAIMER

This is not a guarantee of payment, coverage, or reimbursement. Intersect ENT does not provide any advice, recommendation, guarantee, or warranty relating to coverage, reimbursement, or coding for any product or service. Healthcare providers are responsible for determining coverage and reimbursement information and ensuring the accuracy and completeness of claim submissions for their patients. Coding, coverage, and reimbursement vary significantly by payer, patient, and setting of care and are subject to change. Additional information may exist. Actual coverage and reimbursement decisions are made by individual payers. Healthcare providers are responsible for consulting payers' policies.

## Billing the National Drug Code (NDC)

When billing physician administered drugs with a J Code, payers may require the 11-digit National Drug Code (NDC) to be included on claims. The 11-digit billable NDC for SINUVA is **10599000301**.

For proper claim filing this information must be captured in a specific format as shown below.

Electronic claims  
(ANSI 5010 837)

		LOOP	SEGMENT
PRODUCT ID QUALIFIER	Enter <b>N4</b> in this field	2410	LIN02
NATIONAL DRUG CODE	Enter 11-digit NDC <b>10599000301</b>	2410	LIN03
NATIONAL DRUG CODE UNIT COUNT	Enter quantity (number of NDC units) <b>1</b> (unilateral) or <b>2</b> (bilateral)	2410	LIN04
UNIT OF MEASURE	Enter NDC unit of measure as <b>UN</b> followed by units billed 1 unit = <b>UN1</b>	2410	CTP05

## CMS-1500 Paper Claim

In the shaded area of Field 24A of the CMS-1500 Form, enter the NDC Qualifier N4 in the first two positions, followed by the 11-digit NDC (NO dashes or spaces) and then a space and the NDC Units of Measure Qualifier (UN), followed by the Quantity 2 for bilateral (two) SINUVA units or Quantity 1 for unilateral (one) SINUVA unit. This information must be left justified in the pink shaded area above the Date of Service. For a SINUVA **bilateral** procedure this should be captured as **N410599000301 UN2**.

See page 1 for NDC input into CMS-1500 Claim Form (reference ).

### INDICATION

SINUVA is a corticosteroid-eluting (mometasone furoate) implant indicated for the treatment of nasal polyps, in patients ≥ 18 years of age who have had ethmoid sinus surgery.

### IMPORTANT SAFETY INFORMATION

#### CONTRAINDICATIONS

Patients with known hypersensitivity to mometasone furoate and any of the ingredients of the SINUVA Sinus Implant.

#### WARNINGS AND PRECAUTIONS

**Local Effects:** Monitor nasal mucosa adjacent to the SINUVA Sinus Implant for any signs of bleeding (epistaxis), irritation, infection, or perforation. Avoid use in patients with nasal ulcers or trauma.

**Ocular Effects:** Monitor patients with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts closely.

**Hypersensitivity Reactions:** Hypersensitivity reactions, including rash, pruritus, and angioedema have been reported with the use of corticosteroids.

**Immunosuppression:** Patients taking corticosteroids are more susceptible to a more serious or even fatal course of chickenpox or measles than healthy individuals. Corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculosis infection of the respiratory tract; untreated systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.

**Hypercorticism and Adrenal Suppression:** If corticosteroid effects such as hypercorticism and adrenal suppression appear in patients, consider sinus implant removal.

There are no studies evaluating repeat implantation of the SINUVA Sinus Implant.

#### ADVERSE REACTIONS

The most common adverse reactions observed (> 1% of subjects and that occurred more frequently in the treatment group compared to control) in clinical studies were asthma, headache, epistaxis, presyncope, bronchitis, otitis media, and nasopharyngitis.

**Rx only. Please see attached Full Prescribing Information for SINUVA also available at [SINUVA.com/hcp](http://SINUVA.com/hcp)**